Chapter 7 Small Ubiquitin-Like Modifiers in Cellular Malignancy and Metastasis

International Review of Cell and Molecular Biology

Volumn 273, Issue C, 2009, Pages 265-311

  Kim, Keun Il ^a   Baek, Sung Hee ^b  

^a Sookmyung Women's University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Cancer; deSUMOylation; SENP; SUMO; SUMOylation; Ubc9

Indexed keywords

ENZYME; EXPORTIN 5; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO PROTEIN; UBIQUITIN;

CANCER GROWTH; CARCINOGENESIS; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; METASTASIS; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SUMOYLATION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DISEASE COURSE; METABOLISM; MOLECULAR GENETICS; NEOPLASM; PATHOLOGY;

AMINO ACID SEQUENCE; ANIMALS; DISEASE PROGRESSION; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; NEOPLASMS; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS;

EID: 59649113473     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1937-6448(08)01807-8     Document Type: Review

References (249)

1. Alkuraya F.S., Saadi I., Lund J.J., Turbe-Doan A., Morton C.C., and Maas R.L. SUMO1 haploinsufficiency leads to cleft lip and palate. Science 313 (2006) 1751
2. Arnaoutov A., and Dasso M. Ran-GTP regulates kinetochore attachment in somatic cells. Cell Cycle 4 (2005) 1161-1165
3. Aslanukov A., Bhowmick R., Guruju M., Oswald J., Raz D., Bush R.A., Sieving P.A., Lu X., Bock C.B., and Ferreira P.A. RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolism. PLoS Genet. 2 (2006) e177
4. Azuma Y., Tan S.H., Cavenagh M.M., Ainsztein A.M., Saitoh H., and Dasso M. Expression and regulation of the mammalian SUMO-1 E1 enzyme. FASEB J. 15 (2001) 1825-1827
5. Azuma Y., Arnaoutov A., and Dasso M. SUMO-2/3 regulates topoisomerase II in mitosis. J. Cell Biol. 163 (2003) 477-487
6. Azuma Y., Arnaoutov A., Anan T., and Dasso M. PIASy mediates SUMO-2 conjugation of Topoisomerase-II on mitotic chromosomes. EMBO J. 24 (2005) 2172-2182
7. Bae S.H., Jeong J.W., Park J.A., Kim S.H., Bae M.K., Choi S.J., and Kim K.W. Sumoylation increases HIF-1α stability and its transcriptional activity. Biochem. Biophys. Res. Commun. 324 (2004) 394-400
8. Bailey D., and O'Hare P. Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1. J. Biol. Chem. 279 (2004) 692-703
9. Balk S.P., and Knudsen K.E. AR, the cell cycle, and prostate cancer. Nucl. Recept. Signal. 6 (2008) e001
10. Bawa-Khalfe T., Cheng J., Wang Z., and Yeh E.T. Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J. Biol. Chem. 282 (2007) 37341-37349
11. Bayer P., Arndt A., Metzger S., Mahajan R., Melchior F., Jaenicke R., and Becker J. Structure determination of the small ubiquitin-related modifier SUMO-1. J. Mol. Biol. 280 (1998) 275-286
12. Ben-Porath I., and Weinberg R.A. When cells get stressed: An integrative view of cellular senescence. J. Clin. Invest. 113 (2004) 8-13
13. Bencsath K.P., Podgorski M.S., Pagala V.R., Slaughter C.A., and Schulman B.A. Identification of a multifunctional binding site on Ubc9p required for Smt3p conjugation. J. Biol. Chem. 277 (2002) 47938-47945
14. Benson M.D., Li Q.J., Kieckhafer K., Dudek D., Whorton M.R., Sunahara R.K., Iniguez-Lluhi J.A., and Martens J.R. SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5. Proc. Natl. Acad. Sci. USA 104 (2007) 1805-1810
15. Bernad R., van der Velde H., Fornerod M., and Pickersgill H. Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export. Mol. Cell. Biol. 24 (2004) 2373-2384
16. Berta M.A., Mazure N., Hattab M., Pouyssegur J., and Brahimi-Horn M.C. SUMOylation of hypoxia-inducible factor-1α reduces its transcriptional activity. Biochem. Biophys. Res. Commun. 360 (2007) 646-652
17. Bischof O., and Dejean A. SUMO is growing senescent. Cell Cycle 6 (2007) 677-681
18. Bischof O., Schwamborn K., Martin N., Werner A., Sustmann C., Grosschedl R., and Dejean A. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol. Cell 22 (2006) 783-794
19. Boddy M.N., Howe K., Etkin L.D., Solomon E., and Freemont P.S. PIC1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13 (1996) 971-982
20. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4 (2004) 793-805
21. Boggio R., Passafaro A., and Chiocca S. Targeting SUMO E1 to ubiquitin ligases: A viral strategy to counteract sumoylation. J. Biol. Chem. 282 (2007) 15376-15382
22. Bohren K.M., Nadkarni V., Song J.H., Gabbay K.H., and Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem. 279 (2004) 27233-27238
23. 2+-charged talon resin. Protein Expr. Purif. 54 (2007) 289-294
24. Brahimi-Horn M.C., Chiche J., and Pouyssegur J. Hypoxia and cancer. J. Mol. Med. 85 (2007) 1301-1307
25. Bredel M., Bredel C., Juric D., Harsh G.R., Vogel H., Recht L.D., and Sikic B.I. High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. Cancer Res. 65 (2005) 4088-4096
26. Brooks C.L., and Gu W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21 (2006) 307-315
27. Carbia-Nagashima A., Gerez J., Perez-Castro C., Paez-Pereda M., Silberstein S., Stalla G.K., Holsboer F., and Arzt E. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1α during hypoxia. Cell 131 (2007) 309-323
28. Chauchereau A., Amazit L., Quesne M., Guiochon-Mantel A., and Milgrom E. Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J. Biol. Chem. 278 (2003) 12335-12343
29. 3 exerts dose-dependent dual effects on APL cells. Blood 89 (1997) 3345-3353
30. Chen L., and Chen J. MDM2-ARF complex regulates p53 sumoylation. Oncogene 22 (2003) 5348-5357
31. Cheng J., Wang D., Wang Z., and Yeh E.T. SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol. Cell. Biol. 24 (2004) 6021-6028
32. Cheng J., Perkins N.D., and Yeh E.T. Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases. J. Biol. Chem. 280 (2005) 14492-14498
33. Cheng J., Bawa T., Lee P., Gong L., and Yeh E.T. Role of desumoylation in the development of prostate cancer. Neoplasia 8 (2006) 667-676
34. Cheng J., Kang X., Zhang S., and Yeh E.T. SUMO-specific protease 1 is essential for stabilization of HIF1α during hypoxia. Cell 131 (2007) 584-595
35. Choi S.J., Chung S.S., Rho E.J., Lee H.W., Lee M.H., Choi H.S., Seol J.H., Baek S.H., Bang O.S., and Chung C.H. Negative modulation of RXRα transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by SUMO-specific protease SUSP1. J. Biol. Chem. 281 (2006) 30669-30677
36. Chook Y.M., Cingolani G., Conti E., Stewart M., Vetter I., and Wittinghofer A. Pictures in cell biology. Structures of nuclear-transport components. Trends Cell Biol. 9 (1999) 310-311
37. Ciechanover A. The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J. 17 (1998) 7151-7160
38. Collado M., and Serrano M. The senescent side of tumor suppression. Cell Cycle 4 (2005) 1722-1724
39. Collavin L., Gostissa M., Avolio F., Secco P., Ronchi A., Santoro C., and Del S.G. Modification of the erythroid transcription factor GATA-1 by SUMO-1. Proc. Natl. Acad. Sci. USA 101 (2004) 8870-8875
40. Comerford K.M., Leonard M.O., Karhausen J., Carey R., Colgan S.P., and Taylor C.T. Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia. Proc. Natl. Acad. Sci. USA 100 (2003) 986-991
41. Dahle O., Andersen T.O., Nordgard O., Matre V., Del S.G., and Gabrielsen O.S. Transactivation properties of c-Myb are critically dependent on two SUMO-1 acceptor sites that are conjugated in a PIASy enhanced manner. Eur. J. Biochem. 270 (2003) 1338-1348
42. Dai M.S., Jin Y., Gallegos J.R., and Lu H. Balance of Yin and Yang: Ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia 8 (2006) 630-644
43. Daniel A.R., Faivre E.J., and Lange C.A. Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol. Endocrinol. 21 (2007) 2890-2906
44. Dasso M. Emerging roles of the SUMO pathway in mitosis. Cell Div. 3 (2008) 5
45. Dawlaty M.M., and van Deursen J.M. Gene targeting methods for studying nuclear transport factors in mice. Methods 39 (2006) 370-378
46. Dawlaty M.M., Malureanu L., Jeganathan K.B., Kao E., Sustmann C., Tahk S., Shuai K., Grosschedl R., and van Deursen J.M. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIα. Cell 133 (2008) 103-115
47. Deng Z., Wan M., and Sui G. PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger. Mol. Cell. Biol. 27 (2007) 3780-3792
48. Desterro J.M., Thomson J., and Hay R.T. Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett. 417 (1997) 297-300
49. Desterro J.M., Rodriguez M.S., and Hay R.T. SUMO-1 modification of IκBα inhibits NF-κB activation. Mol. Cell 2 (1998) 233-239
50. Desterro J.M., Rodriguez M.S., Kemp G.D., and Hay R.T. Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J. Biol. Chem. 274 (1999) 10618-10624
51. Di B.A., Ouyang J., Lee H.Y., Catic A., Ploegh H., and Gill G. The SUMO-specific protease SENP5 is required for cell division. Mol. Cell. Biol. 26 (2006) 4489-4498
52. Diaz-Martinez L.A., Gimenez-Abian J.F., Azuma Y., Guacci V., Gimenez-Martin G., Lanier L.M., and Clarke D.J. PIASγ is required for faithful chromosome segregation in human cells. PLoS ONE 1 (2006) e53
53. Dong J.T., Lamb P.W., Rinker-Schaeffer C.W., Vukanovic J., Ichikawa T., Isaacs J.T., and Barrett J.C. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268 (1995) 884-886
54. Dong J.T., Suzuki H., Pin S.S., Bova G.S., Schalken J.A., Isaacs W.B., Barrett J.C., and Isaacs J.T. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 56 (1996) 4387-4390
55. Drag M., and Salvesen G.S. DeSUMOylating enzymes-SENPs. IUBMB Life 60 (2008) 734-742
56. Epps J.L., and Tanda S. The Drosophila semushi mutation blocks nuclear import of bicoid during embryogenesis. Curr. Biol. 8 (1998) 1277-1280
57. Everett R.D. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20 (2001) 7266-7273
58. Feigelson H.S., and Henderson B.E. Estrogens and breast cancer. Carcinogenesis 17 (1996) 2279-2284
59. Feng X.H., and Derynck R. Specificity and versatility in TGF-β signaling through Smads. Annu. Rev. Cell Dev. Biol. 21 (2005) 659-693
60. Fu C., Ahmed K., Ding H., Ding X., Lan J., Yang Z., Miao Y., Zhu Y., Shi Y., Zhu J., Huang H., and Yao X. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. Oncogene 24 (2005) 5401-5413
61. Geiss-Friedlander R., and Melchior F. Concepts in sumoylation: A decade on. Nat. Rev. Mol. Cell Biol. 8 (2007) 947-956
62. Ghisletti S., Huang W., Ogawa S., Pascual G., Lin M.E., Willson T.M., Rosenfeld M.G., and Glass C.K. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ. Mol. Cell 25 (2007) 57-70
63. Girdwood D., Bumpass D., Vaughan O.A., Thain A., Anderson L.A., Snowden A.W., Garcia-Wilson E., Perkins N.D., and Hay R.T. P300 transcriptional repression is mediated by SUMO modification. Mol. Cell 11 (2003) 1043-1054
64. Gong L., and Yeh E.T. Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J. Biol. Chem. 281 (2006) 15869-15877
65. Gong L., Millas S., Maul G.G., and Yeh E.T. Differential regulation of sentrinized proteins by a novel sentrin-specific protease. J. Biol. Chem. 275 (2000) 3355-3359
66. Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., Scheffner M., and Del S.G. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 18 (1999) 6462-6471
67. Gregoire S., and Yang X.J. Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors. Mol. Cell. Biol. 25 (2005) 2273-2287
68. Guo D., Li M., Zhang Y., Yang P., Eckenrode S., Hopkins D., Zheng W., Purohit S., Podolsky R.H., Muir A., Wang J., Dong Z., et al. A functional variant of SUMO4, a new IκBα modifier, is associated with type 1 diabetes. Nat. Genet. 36 (2004) 837-841
69. Guo D., Han J., Adam B.L., Colburn N.H., Wang M.H., Dong Z., Eizirik D.L., She J.X., and Wang C.Y. Proteomic analysis of SUMO4 substrates in HEK293 cells under serum starvation-induced stress. Biochem. Biophys. Res. Commun. 337 (2005) 1308-1318
70. Gupta G.P., and Massague J. Cancer metastasis: Building a framework. Cell 127 (2006) 679-695
71. Haglund K., and Dikic I. Ubiquitylation and cell signaling. EMBO J. 24 (2005) 3353-3359
72. Haindl M., Harasim T., Eick D., and Muller S. The nucleolar SUMO-specific protease SENP3 reverses SUMO modification of nucleophosmin and is required for rRNA processing. EMBO Rep. 9 (2008) 273-279
73. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
74. Hang J., and Dasso M. Association of the human SUMO-1 protease SENP2 with the nuclear pore. J. Biol. Chem. 277 (2002) 19961-19966
75. Hannich J.T., Lewis A., Kroetz M.B., Li S.J., Heide H., Emili A., and Hochstrasser M. Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J. Biol. Chem. 280 (2005) 4102-4110
76. Harder Z., Zunino R., and McBride H. Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission. Curr. Biol. 14 (2004) 340-345
77. Hay R.T. SUMO: A history of modification. Mol. Cell 18 (2005) 1-12
78. Hay R.T. SUMO-specific proteases: A twist in the tail. Trends Cell Biol. 17 (2007) 370-376
79. Hershko A., and Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67 (1998) 425-479
80. Hicke L. Protein regulation by monoubiquitin. Nat. Rev. Mol. Cell Biol. 2 (2001) 195-201
81. Hietakangas V., Ahlskog J.K., Jakobsson A.M., Hellesuo M., Sahlberg N.M., Holmberg C.I., Mikhailov A., Palvimo J.J., Pirkkala L., and Sistonen L. Phosphorylation of serine 303 is a prerequisite for the stress-inducible SUMO modification of heat shock factor 1. Mol. Cell. Biol. 23 (2003) 2953-2968
82. Hietakangas V., Anckar J., Blomster H.A., Fujimoto M., Palvimo J.J., Nakai A., and Sistonen L. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc. Natl. Acad. Sci. USA 103 (2006) 45-50
83. Hochstrasser M. Ubiquitin-dependent protein degradation. Annu. Rev. Genet. 30 (1996) 405-439
84. Hochstrasser M. SP-RING for SUMO: New functions bloom for a ubiquitin-like protein. Cell 107 (2001) 5-8
85. Huang L.E., Gu J., Schau M., and Bunn H.F. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95 (1998) 7987-7992
86. Huang T.T., Wuerzberger-Davis S.M., Wu Z.H., and Miyamoto S. Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 115 (2003) 565-576
87. Huang W.C., Ko T.P., Li S.S., and Wang A.H. Crystal structures of the human SUMO-2 protein at 1.6 A and 1.2 A resolution: Implication on the functional differences of SUMO proteins. Eur. J. Biochem. 271 (2004) 4114-4122
88. Hunter T. The age of crosstalk: Phosphorylation, ubiquitination, and beyond. Mol. Cell 28 (2007) 730-738
89. Hutten S., and Kehlenbach R.H. Nup214 is required for CRM1-dependent nuclear protein export in vivo. Mol. Cell. Biol. 26 (2006) 6772-6785
90. Itahana Y., Yeh E.T., and Zhang Y. Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol. Cell. Biol. 26 (2006) 4675-4689
91. Johnson E.S., and Blobel G. Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J. Biol. Chem. 272 (1997) 26799-26802
92. Johnson E.S., Schwienhorst I., Dohmen R.J., and Blobel G. The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J. 16 (1997) 5509-5519
93. Jones D., Crowe E., Stevens T.A., and Candido E.P. Functional and phylogenetic analysis of the ubiquitylation system in Caenorhabditis elegans: Ubiquitin-conjugating enzymes, ubiquitin-activating enzymes, and ubiquitin-like proteins. Genome Biol. 3 (2002) RESEARCH0002
94. Jones M.C., Fusi L., Higham J.H., bdel-Hafiz H., Horwitz K.B., Lam E.W., and Brosens J.J. Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. Proc. Natl. Acad. Sci. USA 103 (2006) 16272-16277
95. Joseph J., Tan S.H., Karpova T.S., McNally J.G., and Dasso M. SUMO-1 targets RanGAP1 to kinetochores and mitotic spindles. J. Cell Biol. 156 (2002) 595-602
96. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., and Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9 (2003) 213-219
97. Joseph J., Liu S.T., Jablonski S.A., Yen T.J., and Dasso M. The RanGAP1-RanBP2 complex is essential for microtubule-kinetochore interactions in vivo. Curr. Biol. 14 (2004) 611-617
98. Kagey M.H., Melhuish T.A., and Wotton D. The polycomb protein Pc2 is a SUMO E3. Cell 113 (2003) 127-137
99. Kahyo T., Nishida T., and Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell 8 (2001) 713-718
100. Kang J.S., Saunier E.F., Akhurst R.J., and Derynck R. The type I TGF-β receptor is covalently modified and regulated by sumoylation. Nat. Cell Biol. 10 (2008) 654-664
101. Karin M. NF-κB and cancer: Mechanisms and targets. Mol. Carcinog. 45 (2006) 355-361
102. Karin M. Nuclear factor-κB in cancer development and progression. Nature 441 (2006) 431-436
103. Karvonen U., Jaaskelainen T., Rytinki M., Kaikkonen S., and Palvimo J.J. ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator. J. Mol. Biol. 382 (2008) 585-600
104. Katayama A., Ogino T., Bandoh N., Takahara M., Kishibe K., Nonaka S., and Harabuchi Y. Overexpression of small ubiquitin-related modifier-1 and sumoylated Mdm2 in oral squamous cell carcinoma: Possible involvement in tumor proliferation and prognosis. Int. J. Oncol. 31 (2007) 517-524
105. Kawana Y., Komiya A., Ueda T., Nihei N., Kuramochi H., Suzuki H., Yatani R., Imai T., Dong J.T., Imai T., Yoshie O., Barrett J.C., et al. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate 32 (1997) 205-213
106. Kerscher O., Felberbaum R., and Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22 (2006) 159-180
107. Kim K.I., and Baek S.H. SUMOylation code in cancer development and metastasis. Mol. Cells 22 (2006) 247-253
108. Kim K.I., Baek S.H., Jeon Y.J., Nishimori S., Suzuki T., Uchida S., Shimbara N., Saitoh H., Tanaka K., and Chung C.H. A new SUMO-1-specific protease, SUSP1, that is highly expressed in reproductive organs. J. Biol. Chem. 275 (2000) 14102-14106
109. Kim J.H., Kim B., Cai L., Choi H.J., Ohgi K.A., Tran C., Chen C., Chung C.H., Huber O., Rose D.W., Sawyers C.L., et al. Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes. Nature 434 (2005) 921-926
110. Kim Y.H., Sung K.S., Lee S.J., Kim Y.O., Choi C.Y., and Kim Y. Desumoylation of homeodomain-interacting protein kinase 2 (HIPK2) through the cytoplasmic-nuclear shuttling of the SUMO-specific protease SENP1. FEBS Lett. 579 (2005) 6272-6278
111. Kim J.H., Choi H.J., Kim B., Kim M.H., Lee J.M., Kim I.S., Lee M.H., Choi S.J., Kim K.I., Kim S.I., Chung C.H., and Baek S.H. Roles of sumoylation of a reptin chromatin-remodelling complex in cancer metastasis. Nat. Cell Biol. 8 (2006) 631-639
112. Kim J.H., Lee J.M., Nam H.J., Choi H.J., Yang J.W., Lee J.S., Kim M.H., Kim S.I., Chung C.H., Kim K.I., and Baek S.H. SUMOylation of pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells. Proc. Natl. Acad. Sci. USA 104 (2007) 20793-20798
113. Kirsh O., Seeler J.S., Pichler A., Gast A., Muller S., Miska E., Mathieu M., Harel-Bellan A., Kouzarides T., Melchior F., and Dejean A. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J. 21 (2002) 2682-2691
114. Knipscheer P., Flotho A., Klug H., Olsen J.V., van Dijk W.J., Fish A., Johnson E.S., Mann M., Sixma T.K., and Pichler A. Ubc9 sumoylation regulates SUMO target discrimination. Mol. Cell 31 (2008) 371-382
115. Kotaja N., Karvonen U., Janne O.A., and Palvimo J.J. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol. Cell. Biol. 22 (2002) 5222-5234
116. Kotaja N., Karvonen U., Janne O.A., and Palvimo J.J. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J. Biol. Chem. 277 (2002) 30283-30288
117. Kuo H.Y., Chang C.C., Jeng J.C., Hu H.M., Lin D.Y., Maul G.G., Kwok R.P., and Shih H.M. SUMO modification negatively modulates the transcriptional activity of CREB-binding protein via the recruitment of Daxx. Proc. Natl. Acad. Sci. USA 102 (2005) 16973-16978
118. Kwek S.S., Derry J., Tyner A.L., Shen Z., and Gudkov A.V. Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene 20 (2001) 2587-2599
119. 3-induced PML or PML/retinoic acid receptor α degradation. J. Exp. Med. 193 (2001) 1361-1371
120. Lallemand-Breitenbach V., Jeanne M., Benhenda S., Nasr R., Lei M., Peres L., Zhou J., Zhu J., Raught B., and de The H. Arsenic degrades PML or PML-RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10 (2008) 547-555
121. Lanari C., and Molinolo A.A. Progesterone receptors-Animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: Possible implications for breast biology and cancer. Breast Cancer Res. 4 (2002) 240-243
122. Lapenta V., Chiurazzi P., van der Spek P., Pizzuti A., Hanaoka F., and Brahe C. SMT3A, a human homologue of the S. cerevisiae SMT3 gene, maps to chromosome 21qter and defines a novel gene family. Genomics 40 (1997) 362-366
123. Lavin M.F., and Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 13 (2006) 941-950
124. Lee G.W., Melchior F., Matunis M.J., Mahajan R., Tian Q., and Anderson P. Modification of Ran GTPase-activating protein by the small ubiquitin-related modifier SUMO-1 requires Ubc9, an E2-type ubiquitin-conjugating enzyme homologue. J. Biol. Chem. 273 (1998) 6503-6507
125. Lee M.B., Lebedeva L.A., Suzawa M., Wadekar S.A., Desclozeaux M., and Ingraham H.A. The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification. Mol. Cell. Biol. 25 (2005) 1879-1890
126. Lee M.H., Lee S.W., Lee E.J., Choi S.J., Chung S.S., Lee J.I., Cho J.M., Seol J.H., Baek S.H., Kim K.I., Chiba T., Tanaka K., et al. SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. Nat. Cell Biol. 8 (2006) 1424-1431
127. Lee J., Lee Y., Lee M.J., Park E., Kang S.H., Chung C.H., Lee K.H., and Kim K. Dual modification of BMAL1 by SUMO2/3 and ubiquitin promotes circadian activation of the CLOCK/BMAL1 complex. Mol. Cell. Biol 28 (2008) 6056-6065
128. Leivonen S.K., and Kahari V.M. Transforming growth factor-β signaling in cancer invasion and metastasis. Int. J. Cancer 121 (2007) 2119-2124
129. Li S.J., and Hochstrasser M. A new protease required for cell-cycle progression in yeast. Nature 398 (1999) 246-251
130. Li S.J., and Hochstrasser M. The yeast ULP2 (SMT4) gene encodes a novel protease specific for the ubiquitin-like Smt3 protein. Mol. Cell. Biol. 20 (2000) 2367-2377
131. Li T., Santockyte R., Shen R.F., Tekle E., Wang G., Yang D.C., and Chock P.B. Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways. J. Biol. Chem. 281 (2006) 36221-36227
132. Li B., Zhou J., Liu P., Hu J., Jin H., Shimono Y., Takahashi M., and Xu G. Polycomb protein Cbx4 promotes SUMO modification of de novo DNA methyltransferase Dnmt3a. Biochem. J. 405 (2007) 369-378
133. Li X., Luo Y., Yu L., Lin Y., Luo D., Zhang H., He Y., Kim Y.O., Kim Y., Tang S., and Min W. SENP1 mediates TNF-induced desumoylation and cytoplasmic translocation of HIPK1 to enhance ASK1-dependent apoptosis. Cell Death Differ. 15 (2008) 739-750
134. Lima C.D., and Reverter D. Structure of the human SENP7 catalytic domain and poly-SUMO deconjugation activities for SENP6 and SENP7. J. Biol. Chem. 283 (2008) 32045-32055
135. Lin W.W., and Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117 (2007) 1175-1183
136. Liu W.M., and Zhang X.A. KAI1/CD82, a tumor metastasis suppressor. Cancer Lett. 240 (2006) 183-194
137. Liu Q., Jin C., Liao X., Shen Z., Chen D.J., and Chen Y. The binding interface between an E2 (UBC9) and a ubiquitin homologue (UBL1). J. Biol. Chem. 274 (1999) 16979-16987
138. Liu B., Mink S., Wong K.A., Stein N., Getman C., Dempsey P.W., Wu H., and Shuai K. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat. Immunol. 5 (2004) 891-898
139. Liu B., Yang R., Wong K.A., Getman C., Stein N., Teitell M.A., Cheng G., Wu H., and Shuai K. Negative regulation of NF-κB signaling by PIAS1. Mol. Cell. Biol. 25 (2005) 1113-1123
140. Liu B., Yang Y., Chernishof V., Loo R.R., Jang H., Tahk S., Yang R., Mink S., Shultz D., Bellone C.J., Loo J.A., and Shuai K. Proinflammatory stimuli induce IKKα-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell 129 (2007) 903-914
141. Long J., Zuo D., and Park M. Pc2-mediated sumoylation of Smad-interacting protein 1 attenuates transcriptional repression of E-cadherin. J. Biol. Chem. 280 (2005) 35477-35489
142. Lyst M.J., Nan X., and Stancheva I. Regulation of MBD1-mediated transcriptional repression by SUMO and PIAS proteins. EMBO J. 25 (2006) 5317-5328
143. Mabb A.M., Wuerzberger-Davis S.M., and Miyamoto S. PIASy mediates NEMO sumoylation and NF-κB activation in response to genotoxic stress. Nat. Cell Biol. 8 (2006) 986-993
144. Mahajan R., Delphin C., Guan T., Gerace L., and Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 88 (1997) 97-107
145. Mannen H., Tseng H.M., Cho C.L., and Li S.S. Cloning and expression of human homolog HSMT3 to yeast SMT3 suppressor of MIF2 mutations in a centromere protein gene. Biochem. Biophys. Res. Commun. 222 (1996) 178-180
146. Mantovani A., Allavena P., Sica A., and Balkwill F. Cancer-related inflammation. Nature 454 (2008) 436-444
147. Matic I., van Hagen M., Schimmel J., Macek B., Ogg S.C., Tatham M.H., Hay R.T., Lamond A.I., Mann M., and Vertegaal A.C. In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol. Cell Proteomics 7 (2008) 132-144
148. Matunis M.J., Coutavas E., and Blobel G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 135 (1996) 1457-1470
149. Matunis M.J., Wu J., and Blobel G. SUMO-1 modification and its role in targeting the Ran GTPase-activating protein, RanGAP1, to the nuclear pore complex. J. Cell Biol. 140 (1998) 499-509
150. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
151. Meluh P.B., and Koshland D. Evidence that the MIF2 gene of Saccharomyces cerevisiae encodes a centromere protein with homology to the mammalian centromere protein CENP-C. Mol. Biol. Cell 6 (1995) 793-807
152. Mikolajczyk J., Drag M., Bekes M., Cao J.T., Ronai Z., and Salvesen G.S. Small ubiquitin-related modifier (SUMO)-specific proteases: Profiling the specificities and activities of human SENPs. J. Biol. Chem. 282 (2007) 26217-26224
153. Mo Y.Y., Yu Y., Ee P.L., and Beck W.T. Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs. Cancer Res. 64 (2004) 2793-2798
154. Mo Y.Y., Yu Y., Theodosiou E., Rachel Ee P.L., and Beck W.T. A role for Ubc9 in tumorigenesis. Oncogene 24 (2005) 2677-2683
155. Morita Y., Kanei-Ishii C., Nomura T., and Ishii S. TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation. Mol. Biol. Cell 16 (2005) 5433-5444
156. Mukhopadhyay D., Ayaydin F., Kolli N., Tan S.H., Anan T., Kametaka A., Azuma Y., Wilkinson K.D., and Dasso M. SUSP1 antagonizes formation of highly SUMO2/3-conjugated species. J. Cell Biol. 174 (2006) 939-949
157. Muller S., Matunis M.J., and Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17 (1998) 61-70
158. Muller S., Berger M., Lehembre F., Seeler J.S., Haupt Y., and Dejean A. c-Jun and p53 activity is modulated by SUMO-1 modification. J. Biol. Chem. 275 (2000) 13321-13329
159. Nacerddine K., Lehembre F., Bhaumik M., Artus J., Cohen-Tannoudji M., Babinet C., Pandolfi P.P., and Dejean A. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev. Cell 9 (2005) 769-779
160. Nakagawa K., and Yokosawa H. PIAS3 induces SUMO-1 modification and transcriptional repression of IRF-1. FEBS Lett. 530 (2002) 204-208
161. Nguyen H.V., Chen J.L., Zhong J., Kim K.J., Crandall E.D., Borok Z., Chen Y., and Ann D.K. SUMOylation attenuates sensitivity toward hypoxia- or desferroxamine-induced injury by modulating adaptive responses in salivary epithelial cells. Am. J. Pathol. 168 (2006) 1452-1463
162. Nishida T., and Yasuda H. PIAS1 and PIASxα function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. J. Biol. Chem. 277 (2002) 41311-41317
163. Nishida T., Tanaka H., and Yasuda H. A novel mammalian Smt3-specific isopeptidase 1 (SMT3IP1) localized in the nucleolus at interphase. Eur. J. Biochem. 267 (2000) 6423-6427
164. Ohshima T., Koga H., and Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J. Biol. Chem. 279 (2004) 29551-29557
165. Okuma T., Honda R., Ichikawa G., Tsumagari N., and Yasuda H. In vitro SUMO-1 modification requires two enzymatic steps, E1 and E2. Biochem. Biophys. Res. Commun. 254 (1999) 693-698
166. Okura T., Gong L., Kamitani T., Wada T., Okura I., Wei C.F., Chang H.M., and Yeh E.T. Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol. 157 (1996) 4277-4281
167. Owerbach D., McKay E.M., Yeh E.T., Gabbay K.H., and Bohren K.M. A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem. Biophys. Res. Commun. 337 (2005) 517-520
168. Oyanagi H., Takenaka K., Ishikawa S., Kawano Y., Adachi Y., Ueda K., Wada H., and Tanaka F. Expression of LUN gene that encodes a novel RING finger protein is correlated with development and progression of non-small cell lung cancer. Lung Cancer 46 (2004) 21-28
169. Pardali K., and Moustakas A. Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim. Biophys. Acta 1775 (2007) 21-62
170. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., and Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437 (2005) 759-763
171. Pichler A., Gast A., Seeler J.S., Dejean A., and Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 108 (2002) 109-120
172. Pichler A., Knipscheer P., Oberhofer E., van Dijk W.J., Korner R., Olsen J.V., Jentsch S., Melchior F., and Sixma T.K. SUMO modification of the ubiquitin-conjugating enzyme E2-25K. Nat. Struct. Mol. Biol. 12 (2005) 264-269
173. Potts P.R., and Yu H. Human MMS21/NSE2 is a SUMO ligase required for DNA repair. Mol. Cell. Biol. 25 (2005) 7021-7032
174. Potts P.R., and Yu H. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat. Struct. Mol. Biol. 14 (2007) 581-590
175. Poukka H., Karvonen U., Janne O.A., and Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. USA 97 (2000) 14145-14150
176. Prudden J., Pebernard S., Raffa G., Slavin D.A., Perry J.J., Tainer J.A., McGowan C.H., and Boddy M.N. SUMO-targeted ubiquitin ligases in genome stability. EMBO J. 26 (2007) 4089-4101
177. Pungaliya P., Kulkarni D., Park H.J., Marshall H., Zheng H., Lackland H., Saleem A., and Rubin E.H. TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins. J. Proteome Res. 6 (2007) 3918-3923
178. Rajendra R., Malegaonkar D., Pungaliya P., Marshall H., Rasheed Z., Brownell J., Liu L.F., Lutzker S., Saleem A., and Rubin E.H. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J. Biol. Chem. 279 (2004) 36440-36444
179. Regad T., and Chelbi-Alix M.K. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20 (2001) 7274-7286
180. Reverter D., and Lima C.D. Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 435 (2005) 687-692
181. Reverter D., and Lima C.D. Structural basis for SENP2 protease interactions with SUMO precursors and conjugated substrates. Nat. Struct. Mol. Biol. 13 (2006) 1060-1068
182. Rodriguez M.S., Desterro J.M., Lain S., Midgley C.A., Lane D.P., and Hay R.T. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18 (1999) 6455-6461
183. Rodriguez M.S., Dargemont C., and Hay R.T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276 (2001) 12654-12659
184. Rogers R.S., Horvath C.M., and Matunis M.J. SUMO modification of STAT1 and its role in PIAS-mediated inhibition of gene activation. J. Biol. Chem. 278 (2003) 30091-30097
185. Roscic A., Moller A., Calzado M.A., Renner F., Wimmer V.C., Gresko E., Ludi K.S., and Schmitz M.L. Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2. Mol. Cell 24 (2006) 77-89
186. Roth W., Sustmann C., Kieslinger M., Gilmozzi A., Irmer D., Kremmer E., Turck C., and Grosschedl R. PIASy-deficient mice display modest defects in IFN and Wnt signaling. J. Immunol. 173 (2004) 6189-6199
187. Roukens M.G., loul-Ramdhani M., Vertegaal A.C., Anvarian Z., Balog C.I., Deelder A.M., Hensbergen P.J., and Baker D.A. Identification of a new site of sumoylation on Tel (ETV6) uncovers a PIAS-dependent mode of regulating Tel function. Mol. Cell. Biol. 28 (2008) 2342-2357
188. Sachdev S., Bruhn L., Sieber H., Pichler A., Melchior F., and Grosschedl R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 15 (2001) 3088-3103
189. Sahai E. Illuminating the metastatic process. Nat. Rev. Cancer 7 (2007) 737-749
190. Saitoh H., and Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275 (2000) 6252-6258
191. Saitoh H., Sparrow D.B., Shiomi T., Pu R.T., Nishimoto T., Mohun T.J., and Dasso M. Ubc9p and the conjugation of SUMO-1 to RanGAP1 and RanBP2. Curr. Biol. 8 (1998) 121-124
192. Saleem A., Dutta J., Malegaonkar D., Rasheed F., Rasheed Z., Rajendra R., Marshall H., Luo M., Li H., and Rubin E.H. The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor. Oncogene 23 (2004) 5293-5300
193. Salina D., Enarson P., Rattner J.B., and Burke B. Nup358 integrates nuclear envelope breakdown with kinetochore assembly. J. Cell Biol. 162 (2003) 991-1001
194. Sampson D.A., Wang M., and Matunis M.J. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 276 (2001) 21664-21669
195. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14 (2001) 778-809 Table of contents
196. Santti H., Mikkonen L., Anand A., Hirvonen-Santti S., Toppari J., Panhuysen M., Vauti F., Perera M., Corte G., Wurst W., Janne O.A., and Palvimo J.J. Disruption of the murine PIASx gene results in reduced testis weight. J. Mol. Endocrinol. 34 (2005) 645-654
197. Schimmel J., Larsen K.M., Matic I., van Hagen M., Cox J., Mann M., Andersen J.S., and Vertegaal A.C. The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle. Mol. Cell Proteomics 7 (2008) 2107-2122
198. Schmidt D., and Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc. Natl. Acad. Sci. USA 99 (2002) 2872-2877
199. Schmidt D., and Muller S. PIAS/SUMO: New partners in transcriptional regulation. Cell. Mol. Life Sci. 60 (2003) 2561-2574
200. Schofield C.J., and Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 5 (2004) 343-354
201. Schwarz S.E., Matuschewski K., Liakopoulos D., Scheffner M., and Jentsch S. The ubiquitin-like proteins SMT3 and SUMO-1 are conjugated by the UBC9 E2 enzyme. Proc. Natl. Acad. Sci. USA 95 (1998) 560-564
202. Sentis S., Le R.M., Bianchin C., Rostan M.C., and Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol. Endocrinol. 19 (2005) 2671-2684
203. Seufert W., Futcher B., and Jentsch S. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature 373 (1995) 78-81
204. Shao W., Fanelli M., Ferrara F.F., Riccioni R., Rosenauer A., Davison K., Lamph W.W., Waxman S., Pelicci P.G., Lo C.F., Avvisati G., Testa U., et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 90 (1998) 124-133
205. Shao R., Zhang F.P., Tian F., Anders F.P., Wang X., Sjoland H., and Billig H. Increase of SUMO-1 expression in response to hypoxia: Direct interaction with HIF-1α in adult mouse brain and heart in vivo. FEBS Lett. 569 (2004) 293-300
206. Shen Z., Pardington-Purtymun P.E., Comeaux J.C., Moyzis R.K., and Chen D.J. UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins. Genomics 36 (1996) 271-279
207. Shuai K., and Liu B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3 (2003) 900-911
208. Shuai K., and Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat. Rev. Immunol. 5 (2005) 593-605
209. Sramko M., Markus J., Kabat J., Wolff L., and Bies J. Stress-induced inactivation of the c-Myb transcription factor through conjugation of SUMO-2/3 proteins. J. Biol. Chem. 281 (2006) 40065-40075
210. Stankovic-Valentin N., Deltour S., Seeler J., Pinte S., Vergoten G., Guerardel C., Dejean A., and Leprince D. An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved ψKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol. Cell. Biol. 27 (2007) 2661-2675
211. Subramanian L., Benson M.D., and Iniguez-Lluhi J.A. A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3. J. Biol. Chem. 278 (2003) 9134-9141
212. Sun H., Leverson J.D., and Hunter T. Conserved function of RNF4 family proteins in eukaryotes: Targeting a ubiquitin ligase to SUMOylated proteins. EMBO J. 26 (2007) 4102-4112
213. Sutter C.H., Laughner E., and Semenza G.L. Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc. Natl. Acad. Sci. USA 97 (2000) 4748-4753
214. Tahk S., Liu B., Chernishof V., Wong K.A., Wu H., and Shuai K. Control of specificity and magnitude of NF-κB and STAT1-mediated gene activation through PIASy and PIAS1 cooperation. Proc. Natl. Acad. Sci. USA 104 (2007) 11643-11648
215. Tatham M.H., Jaffray E., Vaughan O.A., Desterro J.M., Botting C.H., Naismith J.H., and Hay R.T. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276 (2001) 35368-35374
216. Tatham M.H., Chen Y., and Hay R.T. Role of two residues proximal to the active site of Ubc9 in substrate recognition by the Ubc9.SUMO-1 thiolester complex. Biochemistry 42 (2003) 3168-3179
217. Tatham M.H., Kim S., Jaffray E., Song J., Chen Y., and Hay R.T. Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection. Nat. Struct. Mol. Biol. 12 (2005) 67-74
218. Tatham M.H., Geoffroy M.C., Shen L., Plechanovova A., Hattersley N., Jaffray E.G., Palvimo J.J., and Hay R.T. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10 (2008) 538-546
219. Tsai Y.C., Mendoza A., Mariano J.M., Zhou M., Kostova Z., Chen B., Veenstra T., Hewitt S.M., Helman L.J., Khanna C., and Weissman A.M. The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat. Med. 13 (2007) 1504-1509
220. Uchida S., Shimada Y., Watanabe G., Li Z.G., Hong T., Miyake M., and Imamura M. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br. J. Cancer 79 (1999) 1168-1173
221. Ungureanu D., Vanhatupa S., Kotaja N., Yang J., Aittomaki S., Janne O.A., Palvimo J.J., and Silvennoinen O. PIAS proteins promote SUMO-1 conjugation to STAT1. Blood 102 (2003) 3311-3313
222. Uzunova K., Gottsche K., Miteva M., Weisshaar S.R., Glanemann C., Schnellhardt M., Niessen M., Scheel H., Hofmann K., Johnson E.S., Praefcke G.J., and Dohmen R.J. Ubiquitin-dependent proteolytic control of SUMO conjugates. J. Biol. Chem. 282 (2007) 34167-34175
223. Vertegaal A.C., Andersen J.S., Ogg S.C., Hay R.T., Mann M., and Lamond A.I. Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol. Cell Proteomics 5 (2006) 2298-2310
224. Wang C.Y., and She J.X. SUMO4 and its role in type 1 diabetes pathogenesis. Diabetes Metab. Res. Rev. 24 (2008) 93-102
225. Watts F.Z. The role of SUMO in chromosome segregation. Chromosoma 116 (2007) 15-20
226. Weger S., Hammer E., and Heilbronn R. Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett. 579 (2005) 5007-5012
227. Weisshaar S.R., Keusekotten K., Krause A., Horst C., Springer H.M., Gottsche K., Dohmen R.J., and Praefcke G.J. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML. FEBS Lett. 582 (2008) 3174-3178
228. Welchman R.L., Gordon C., and Mayer R.J. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat. Rev. Mol. Cell Biol. 6 (2005) 599-609
229. Wohlschlegel J.A., Johnson E.S., Reed S.I., and Yates III J.R. Global analysis of protein sumoylation in Saccharomyces cerevisiae. J. Biol. Chem. 279 (2004) 45662-45668
230. Wong K.A., Kim R., Christofk H., Gao J., Lawson G., and Wu H. Protein inhibitor of activated STAT Y (PIASy) and a splice variant lacking exon 6 enhance sumoylation but are not essential for embryogenesis and adult life. Mol. Cell. Biol. 24 (2004) 5577-5586
231. Wotton D., and Merrill J.C. Pc2 and SUMOylation. Biochem. Soc. Trans. 35 (2007) 1401-1404
232. Wu H., Sun L., Zhang Y., Chen Y., Shi B., Li R., Wang Y., Liang J., Fan D., Wu G., Wang D., Li S., et al. Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation. J. Biol. Chem. 281 (2006) 21848-21856
233. Wuerzberger-Davis S.M., Nakamura Y., Seufzer B.J., and Miyamoto S. NF-κB activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage. Oncogene 26 (2007) 641-651
234. Xie Y., Kerscher O., Kroetz M.B., McConchie H.F., Sung P., and Hochstrasser M. The yeast Hex3.Slx8 heterodimer is a ubiquitin ligase stimulated by substrate sumoylation. J. Biol. Chem. 282 (2007) 34176-34184
235. Xirodimas D.P., Chisholm J., Desterro J.M., Lane D.P., and Hay R.T. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett. 528 (2002) 207-211
236. Xu Z., and Au S.W. Mapping residues of SUMO precursors essential in differential maturation by SUMO-specific protease, SENP1. Biochem. J. 386 (2005) 325-330
237. Yamaguchi T., Sharma P., Athanasiou M., Kumar A., Yamada S., and Kuehn M.R. Mutation of SENP1/SuPr-2 reveals an essential role for desumoylation in mouse development. Mol. Cell. Biol. 25 (2005) 5171-5182
238. Yang X., Wei L., Tang C., Slack R., Montgomery E., and Lippman M. KAI1 protein is down-regulated during the progression of human breast cancer. Clin. Cancer Res. 6 (2000) 3424-3429
239. Yang S.H., Jaffray E., Hay R.T., and Sharrocks A.D. Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol. Cell 12 (2003) 63-74
240. Yates K.E., Korbel G.A., Shtutman M., Roninson I.B., and Dimaio D. Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts. Aging Cell 7 (2008) 609-621
241. Yeh E.T., Gong L., and Kamitani T. Ubiquitin-like proteins: New wines in new bottles. Gene 248 (2000) 1-14
242. Yu Y., Yang J.L., Markovic B., Jackson P., Yardley G., Barrett J., and Russell P.J. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin. Cancer Res. 3 (1997) 1045-1049
243. Zhang H., Saitoh H., and Matunis M.J. Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex. Mol. Cell. Biol. 22 (2002) 6498-6508
244. Zhang F.P., Mikkonen L., Toppari J., Palvimo J.J., Thesleff I., and Janne O.A. Sumo-1 function is dispensable in normal mouse development. Mol. Cell. Biol. 28 (2008) 5381-5390
245. Zhang X.D., Goeres J., Zhang H., Yen T.J., Porter A.C., and Matunis M.J. SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Mol. Cell 29 (2008) 729-741
246. Zhao X., and Blobel G. A SUMO ligase is part of a nuclear multiprotein complex that affects DNA repair and chromosomal organization. Proc. Natl. Acad. Sci. USA 102 (2005) 4777-4782
247. Zhao X., Sternsdorf T., Bolger T.A., Evans R.M., and Yao T.P. Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. Mol. Cell. Biol. 25 (2005) 8456-8464
248. Zhu J., Koken M.H., Quignon F., Chelbi-Alix M.K., Degos L., Wang Z.Y., Chen Z., and de The H. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94 (1997) 3978-3983
249. Zunino R., Schauss A., Rippstein P., Andrade-Navarro M., and McBride H.M. The SUMO protease SENP5 is required to maintain mitochondrial morphology and function. J. Cell Sci. 120 (2007) 1178-1188